poisar

Stocks · News reference

Royalty Pharma shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint. The company had signed a $500 million funding agreement with Novartis partner Ionis that would have contributed pelacarsen royalties.

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

    The iShares U.S. Pharmaceuticals ETF (IHE) is reviewed as a reasonable option for investors seeking broad exposure to the Healthcare-Pharma sector. With $1.69 billion in assets and a 0.37% expense ratio, the fund has delivered strong year-to-date returns of 28.8% and one-year returns of 35.48%. However, it carries higher risk with a beta of 0.47 and standard deviation of 17.13%. Top holdings include Eli Lilly (26.88%), Johnson & Johnson, and Royalty Pharma, with the top 10 holdings representing 81.09% of assets.

  2. Fiscal.ai

    Royalty Pharma Announces 2030 Financial Outlook

    Royalty Pharma has released a long-term financial outlook targeting over $4.7 billion in annual portfolio receipts and more than $7.50 in portfolio cash flow per share by 2030.

  3. SEC EDGARSEC EDGAR

    8-K filing — Royalty Pharma plc (RPRX)

    Filed: 2026-11-04 AccNo: 0001802768-26-000026 Size: 501 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits